What if we could reduce the size of a phase III study from 400 to 80 subjects and make it twice as short? Thanks to model-informed clinical trial design, it’s possible! Watch this inspiring story based on real-world case study data and learn about Simulx at the same time. In an hour, we will take you from the modeling of phase II studies in Monolix to the estimation of a phase III study power in Simulx to finally optimizing sample size and study duration.
By Claude Magnard